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Objective. Although cannabis is an illegal drug, ‘medical marijuana programs’ (MMPs) have proliferated (e.g., in
Canada and several US states), allowing for legal cannabis use for therapeutic purposes. While both health
risks and potential therapeutic beneﬁts for cannabis use have been documented, potential public health impacts
of MMPs — also vis-à-vis other psychoactive substance use — remain under-explored.
Methods.We brieﬂy reviewed the emerging evidence on MMP participants' health status, and speciﬁcally other
psychoactive substance use behaviors and outcomes.
Results.While data are limited in amount and quality, MMP participants report improvements in overall health
status, and speciﬁcally reductions in levels of risky alcohol, prescription drug and — to some extent — tobacco
or other illicit drug use; at the same time, increases in cannabis use and risk/problem patterns may occur.
Conclusion.MMPparticipationmay positively impact— for example, byway of possible ‘substitution effects’ from
cannabis use— other psychoactive substance use and risk patterns at a scale relevant for public health, also inﬂu-
enced by the increasing population coverage of MMPs. Yet, net overall MMP-related population health effects
need to be more rigorously and comprehensively assessed, including potential increases in cannabis use related
risks and harms.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Cannabis is the most widely used illegal drug globally, and its cur-
rent legal status is being controversially debated (United Nations Drug
Control Programme (UNDCP), 2014; Room, 2014). Despite cannabis' il-
legal status in most places, including Canada, medical marijuana pro-
grams (MMPs) have proliferated in several US states and Canada, as
well as other countries (e.g., UK, Israel, Netherlands) in recent years
(Room, 2014; Hoffmann and Weber, 2010; Procon.org, 2014). MMPs
are publicly regulated programs where individuals, usually following a
medical conﬁrmation of a health condition, are permitted to use mari-
juana for ‘medical’ purposes and thus are exempted from punitive can-
nabis law enforcement that otherwise may apply (Hoffmann and
Weber, 2010; Hall and Degenhardt, 2003). Terminology has evolved
using the term ‘medicalmarijuana use’ (MMU) for thosewhoare partic-
ipants of MMPs, whereas ‘therapeutic’ cannabis use is applied more
generally for use that is assumed to be beneﬁcial for health; this papersearch in Mental Health and
Fraser University, 2400 — 515
782 7768.
. This is an open access article underwill adhere to this use of terminology. We ﬁrst describe the example
of Canada for the emergence and regulatory framing of its MMP, then
brieﬂy review the available evidence on possible population health rel-
evant effects— speciﬁcally vis-à-vis other psychoactive substance use—
related to MMPs, and conclude with comments on potential implica-
tions for public health, policy and future research.
Canada's original MMP was established in 2001, following several
higher court decisions involving constitutional challenges which essen-
tially forced the federal government to facilitate and regulate cannabis
use and access for therapeutic purposes for chronically/severely ill pa-
tients (Belle-Isle et al., 2014; Lucas, 2009; Fischer et al., 2003). The orig-
inal authorization process for MMU involved a rather onerous process.
Consequently, initial utilization of the MMP was quite limited, and
only a few hundred individuals were formally approved in the MMP's
initial years, despite survey data suggesting that as many as 500,000–
1,000,000 Canadians self-characterized their cannabis use as being for
therapeutic purposes (Lucas, 2009; Ogborne and Smart, 2000). As the
number of authorizations under the MMP began to rise, ongoing con-
cerns about process, access and supply issues entailed several program
revisions, ﬁnally leading to the implementation of — completely
overhauled — new MMP regulations in 2014 (Health Canada, 2014b;the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ernment — authorize an individual for MMU; authorization can be
granted for a list of deﬁned severe/chronic conditions, or for any “debil-
itating symptom that is associated with a medical condition or [its]
medical treatment” (Health Canada, 2014b; Fischer et al., 2014). In es-
sence, MMU can now be sanctioned in Canada for any health condition
for which a physician conﬁrms therapeutic beneﬁts from cannabis use
(Health Canada, 2014b). There were 37,000 authorized medical mari-
juana users in Canada by the end of 2013; this population, based on
above-mentioned estimates of self-identiﬁed therapeutic cannabis
users, is expected to grow to as many as 500,000 or more, or N2%, of
the adult Canadian population in the coming years (Health Canada,
2014a). These recent rapid increases in the number ofMMPparticipants
mirror developments in other jurisdictions. For example, obtaining en-
dorsement for MMP participation in California has been rather easy
and ﬂexible, and resulted in a MMP user population of N1,000,000
(California NORML, 2011; Reinarman et al., 2011; Harris et al., 2000).
So why might MMPs matter for public health, and why should we
seek to better understand potential impacts? While not approved as a
medication by key regulatory bodies, cannabis is a psychoactive sub-
stance featuring a variety of health risks next to therapeutic beneﬁts.
For example, cannabis (Gordon et al., 2013; Room et al., 2010; Volkow
et al., 2014; Hall and Degenhardt, 2009)may entail various acute cogni-
tive, memory and/or psychomotor impairments (Crean et al., 2011)
speciﬁcally associated with elevated risk for (e.g., motor-vehicle) acci-
dents or injury. Cannabis use furthermore brings risk for both depen-
dence and psychotic and/or depression problems (Moore et al., 2007),
and is associated with the incidence of different forms of (e.g., lung)
cancers (Mehra et al., 2006; Zhang et al., 1999); moreover, cannabis
use commonly results in other pulmonary and bronchial problems
(Tetrault et al., 2007). Importantly for public health, intensive, frequent
or chronic users are at highest risk for most of the above problems (see
Degenhardt et al., 2013; Fischer et al., 2011; Hall and Pacula, 2003;
Volkow et al., 2014).
Conversely, multiple potential therapeutic beneﬁts are attributed to
cannabis and supported by differing degrees of evidence (Baker et al.,
2003a,b; Ben Amar, 2006; Borgelt et al., 2013; Hazekamp and
Grotenhermen, 2010; Kalant, 2001; Leung, 2011; Robson, 2001). Vari-
ous evidence points to cannabis' effects as an analgesic, especially for
neuropathic pain (Campbell et al., 2001; Martín-Sánchez et al., 2009).
Furthermore, there are indications of beneﬁcial effects from cannabis as
an anti-emetic (Tramèr et al., 2001) and appetite stimulant (e.g., for can-
cer/AIDS related problems) (Kirkham andWilliams, 2001), as well as for
anti-spasticity (Wade et al., 2006) and anti-convulsant (e.g., for multiple
sclerosis, epilepsy) effects (Hill et al., 2012). Cannabismay further reduce
intraocular pressure (e.g., for glaucoma) (Tomida et al., 2004), and exert
broncho-dilating effects (e.g., for asthma) (Ziment and Tashkin, 2000).
Limited evidence also points to potential anti-depressant, anxiolytic, sed-
ative, hypnotic or neuro-protective effects (Gonzalez, 2007; Iversen,
2007; McPartland and Russo, 2001).
Beyond the effects ofMMPparticipation for an individual, an emerg-
ing body of evidence suggests that MMPs may have discernable— both
positive and negative — impacts relevant on a population health level.
Most MMP participants are individuals with severe/chronic, and often
multiple— physical ormental— health problems (e.g., pain, psychiatric,
sleep, gastro-intestinal, MS, arthritis, HIV/AIDS, neurological problems),
many of whom report improved health status/outcomes whichmay re-
sult in reduced health care needs or utilization. For example, among
n=100 CaliforniaMMPparticipants, 59% reportedMMU for N1 chronic
condition; they reported signiﬁcantly higher (average global rating 81
vs. 52; p b .01) effectiveness of MMU over other medication (Harris
et al., 2000). Among n= 348MichiganMMP participants, 87% reported
multiple conditions (mostly pain); improved pain scores, and physical
and mental health function scores, were reported by returning (n =
153) compared to ﬁrst-time (n = 195) MMP patients (Ilgen et al.,
2013). A Hawaii sample of returning MMP patients with mainly painas the principal condition reported a 64% overall reduction in pain
scores following MMP initiation; about half reported relief from
anxiety/stress and insomnia problems (Webb and Webb, 2014).
Among n = 130 San Francisco MMP patients with multiple conditions,
55% reported “better symptom management” from MMU compared to
other prescription drugs (Reiman, 2007); similar data from UK-based
MMP patients reported superior effects from MMU on their symptoms
(Coomber, 2003; Ware et al., 2005). Among n = 628 Canadian MMP
participants largely reportingmultiple chronic conditions, 72% reported
that MMU was “always helpful” and 24% reported that it was “often
helpful” towards “effective symptom relief” (Walsh et al., 2013).
Second, MMP participants indicate extensive histories and/or con-
current alcohol, tobacco, illicit and/or prescription drug use. Each of
these drug use categories is among the major risk factors for acute
and/or chronic morbidity/mortality outcomes, accounting for almost
20% of overall population-level disease burden in North America (Lim
et al., 2012). Importantly, evidence suggests that MMP participation
may be associated especially with reductions of risky patterns of psy-
choactive substance use. For example, among Michigan MMP partici-
pants, the majority (68%) reported non-medical prescription opioid
(PO) use; 45% of the sample ‘intended’ to reduce their non-medical PO
use (Ilgen et al., 2013); therewere signiﬁcant reductions in prescription
sedative use among continuous versus newMMP patients. Among n =
404 Canadian MMP participants, 20% were current illicit drug (other
than cannabis) users, while 27% had a history of substance abuse and
20% past alcohol dependence treatment (Lucas et al., 2013); 76% report-
edMMUas a substitute for other substance use; speciﬁcally, 41% report-
ed substituting cannabis for alcohol, 36% for illicit substances, and 68%
for prescription drugs. Similarly, among San Francisco MMP users, 19%
had analcohol treatment history;while 50% and 47% reported substitut-
ing cannabis for alcohol and illicit drugs, respectively, and 74% reported
substituting cannabis for prescription drugs (Reiman, 2007). Among
California MMP users (n = 4117), about two-thirds (64%) reported a
history of hazardous drinking; when comparing current and pre-MMP
alcohol use, 11% reported abstinence, 28% reported drinking less than
5% of previous peak levels, and 87% reported drinking less than half
(O'Connell and Bou-Matar, 2007); similarly, a majority had reduced
their tobacco use. A California MMP sample reported alleviated anxiety
and sleep problems, and hence potentially reduced need for related
medications (Reinarman et al., 2011). Other studies reported evidence
or potential for reductions in alcohol and/or PO-related problem out-
comes related to cannabis substitution effects (e.g., Clements and
Daryal, 2005; Collen, 2012; Peters and Hughes, 2010; Subbaraman,
2014). A recent population-based study found that the 13 US states
with MMPs had a 24.8% lower mean annual PO-related overdose mor-
tality rate (p b .003) compared with non-MMP states (Bachhuber
et al., 2014), suggesting that MMP implementation may be “protective”
of hazardous PO use, and fatal overdose, on a population level (Hayes
and Brown, 2014).
Third, while MMPs may bring beneﬁts in health status and/or risk
behaviors, these may — at least in part — be offset by increases in
cannabis-related problems or risks co-occurring with MMP participa-
tion. For example, among California MMP users, 59% and 18% had a life-
time or current diagnosis, respectively, for cannabis abuse or
dependence; 90% used cannabis daily or near-daily (Fischer et al.,
2011) — a use pattern that is a primary predictor of subsequent prob-
lems— over multiple years, and 86% smoked on average 2 or more can-
nabis cigarettes per day (Harris et al., 2000). Among Michigan MMP
participants, intensive (i.e., daily) cannabis use was signiﬁcantly more
common (p b 0.0001) among continuous (76%) compared to new
(51%)MMP participants (Ilgen et al., 2013). Majorities (88% and 90% re-
spectively) among California MMP samples reported daily cannabis use
(Janichek and Reiman, 2012; O'Connell and Bou-Matar, 2007). While
most Canadian MMP participants had a pre-MMP cannabis use history,
the majority reported (33% “large”, 32% “small”) increases in cannabis
use post-MMP initiation; 40% reported N2 g/day of use, and 42%
55B. Fischer et al. / Preventive Medicine Reports 2 (2015) 53–56reported N2 use episodes/day (Walsh et al., 2013). Although cannabis-
related harms may increase, they may allow for overall net health ben-
eﬁts, given the relatively limited cannabis-related acute and chronic dis-
ease (e.g., morbidity, mortality) burden compared to other licit or illicit
drugs (e.g., alcohol, opioids)whichmay be reduced in use in the context
of MMPparticipation (Degenhardt and Hall, 2012; Calabria et al., 2010).
The scope and quality of existing evidence characterizing potential
population health effects of MMPs are limited. This is partly an effect
of the emerging nature of this area of knowledge, and likely also related
to the fact that MMPs— at least in North America—were not primarily
implemented as ‘health’ interventions, but rather came about as conse-
quences of developments in the ongoing political and legal struggles
over cannabis control; in Canada, they were a consequence of constitu-
tional court decisions, in US states they were introduced in most in-
stances following public ballot initiatives (Fischer et al., 2014; Lucas,
2009). Besides the sporadic and controversial existence of MMP in
only a few countries, with existent research data mostly restricted to
North America, the illegal status of cannabis has considerably hampered
research into potential therapeutic beneﬁts, and continues to be an ob-
stacle (Hall and Degenhardt, 2003; Cohen, 2010; Abrams, 1998). Based
on the limited evidence available, however, it is a key and timely ques-
tion — within a larger set of questions aiming to better understand the
dynamics between cannabis control options and public health (Fischer
et al., 2009, 2011; Degenhardt et al., 2013; Pacula et al., 2014)—wheth-
erMMPparticipation inﬂuences health behaviors andoutcomes inways
relevant for population health. This need and opportunity is
underscored by the rising MMP uptake and coverage in populations in
different jurisdictions, and should include research in the different
countries where MMPs exist. Respective studies should be rigorous
and systematic, and ideally comparative, and designed based on differ-
ent data andmethods (e.g., involving self-report, clinical and health sys-
tem data).Conﬂict of interest
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